(S)-2-[(R)-2-(4-Benzyloxy-3-methanesulfonylamino-phenyl)-2-hydroxy-ethylamino]-N-tert-butyl-2-(4-methoxy-phenyl)-acetamide | 170688-59-2

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 石蒜科生物碱
• 英文名称: (S)-2-[(R)-2-(4-Benzyloxy-3-methanesulfonylamino-phenyl)-2-hydroxy-ethylamino]-N-tert-butyl-2-(4-methoxy-phenyl)-acetamide
• 英文别名: (2S)-N-tert-butyl-2-[[(2R)-2-hydroxy-2-[3-(methanesulfonamido)-4-phenylmethoxyphenyl]ethyl]amino]-2-(4-methoxyphenyl)acetamide
• CAS: 170688-59-2
• 化学式: C₂₉H₃₇N₃O₆S
• 分子量: 555.695
• InChiKey: BMZZBRSUAXSQIO-BDYUSTAISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  39
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  134
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (S)-2-[(R)-2-(4-Benzyloxy-3-methanesulfonylamino-phenyl)-2-hydroxy-ethylamino]-N-tert-butyl-2-(4-methoxy-phenyl)-acetamide 在 钯 氢气 作用下， 以 甲醇 为溶剂， 生成 (S)-N-tert-Butyl-2-[(R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-2-(4-methoxy-phenyl)-acetamide
  参考文献：
  名称：

  BMS-201620: a selective beta 3 agonist

  摘要：

  A series of N-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamides were prepared and evaluated for their human beta(3) adrenergic receptor agonist activity. SAR studies led to the identification of BMS-201620 (39), a potent beta(3) full agonist (K-i = 93 nM, 93% activation). Based on its favorable safety profile, BMS-201620 was chosen for clinical evaluation. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.074
• 作为产物：
  描述：

  (S)-(N-benzyloxycarbonyl)-p-methoxyphenylglycine 在 palladium dihydroxide 氟化铵 、 氢气 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 (S)-2-[(R)-2-(4-Benzyloxy-3-methanesulfonylamino-phenyl)-2-hydroxy-ethylamino]-N-tert-butyl-2-(4-methoxy-phenyl)-acetamide
  参考文献：
  名称：

  BMS-201620: a selective beta 3 agonist

  摘要：

  A series of N-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamides were prepared and evaluated for their human beta(3) adrenergic receptor agonist activity. SAR studies led to the identification of BMS-201620 (39), a potent beta(3) full agonist (K-i = 93 nM, 93% activation). Based on its favorable safety profile, BMS-201620 was chosen for clinical evaluation. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.074

文献信息

• Catecholamine surrogates useful as B3 agonists
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP0659737A2

  公开（公告）日：1995-06-28

  Compounds of the formula or pharmaceutically acceptable salts thereof wherein: A is a bond, -(CH2)n- or -CH(B)-, where n is an integer of 1 to 3 and B is -CN, -CON(R9)R9' or -C02R7; R1 is lower alkyl, aryl or arylalkyl; R2 is hydrogen, hydroxy, alkoxy, -CH20H, cyano, -C(O)OR7 , -C02H, -CONH2, tetrazole, -CH2NH2 or halogen; R3 is hydrogen, alkyl, heterocycle or R4 is hydrogen, alkyl or B; R5, R5', R8, R8' or R8'' are independently hydrogen, alkoxy, lower alkyl, halogen, -OH, -CN, -(CH2)-nNR6COR7, -CON(R6)R6', -CON(R6)OR6', -C02R6, -SR7, -SOR7, -S02R7, -N(R6)SO2R1, -N(R6)R6', -NR6COR7, -OCH2CON(R6)R6', -OCH2CO2R7 or aryl; or R5 and R5' or R8 and R8' may together with the carbon atoms to which they are attached form an aryl or heterocycle; R6 and R6' are independently hydrogen or lower alkyl; and R7 is lower alkyl; R9 is hydrogen, lower alkyl, alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl; or R9 and R9' may together with the nitrogen atom to which they are attached form a hetocycle; with the proviso that when A is a bond or -(CH2)n and R3 is hydrogen or unsubstituted alkyl, then R4 is B or substituted alkyl. These compounds are beta3 adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity and gastrointestinal diseases.

  式中的化合物 或其药学上可接受的盐类，其中 A 是键、-(CH2)n- 或 -CH(B)-，其中 n 是 1 至 3 的整数，B 是 -CN、-CON(R9)R9' 或 -C02R7； R1 是低级烷基、芳基或芳烷基； R2 是氢、羟基、烷氧基、-CH20H、氰基、-C(O)OR7、-C02H、-CONH2、四唑、-CH2NH2 或卤素； R3 是氢、烷基、杂环或卤素。 R4 是氢、烷基或 B； R5、R5'、R8、R8' 或 R8'' 独立地为氢、烷氧基、低级烷基、卤素、-OH、-CN、-(CH2)-nNR6COR7、-CON(R6)R6'、-C02R6、-SR7、-SOR7、-S02R7、-N(R6)SO2R1、-N(R6)R6'、-NR6COR7、-OCH2CON(R6)R6'、-OCH2CO2R7 或芳基；或 R5 和 R5' 或 R8 和 R8'可与它们所连接的碳原子一起形成芳基或杂环； R6 和 R6'独立地为氢或低级烷基；以及 R7 是低级烷基； R9是氢、低级烷基、烷基、环烷基、芳烷基、芳基、杂芳基；或 R9和R9'可与它们所连接的氮原子一起形成一个杂环；但当A是键或-(CH2)n且R3是氢或未取代的烷基时，则R4是B或取代的烷基。这些化合物是β3肾上腺素能受体激动剂，因此可用于治疗糖尿病、肥胖症和胃肠道疾病等。
• Catecholamine surrogates useful as beta 3 agonists
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP0659737B1

  公开（公告）日：2003-03-26
• BMS-201620: a selective beta 3 agonist
  作者：W.N. Washburn、C.-Q. Sun、G. Bisacchi、G. Wu、P.T. Cheng、P.M. Sher、D. Ryono、A.V. Gavai、K. Poss、R.N. Girotra、P.J. McCann、A.B. Mikkilineni、T.C. Dejneka、T.C. Wang、Z. Merchant、M. Morella、C.M. Arbeeny、T.W. Harper、D.A. Slusarchyk、S. Skwish、A.D. Russell、G.T. Allen、B. Tesfamariam、B.H. Frohlich、B.E. Abboa-Offei、M. Cap、T.L. Waldron、R.J. George、D. Young、K.E. Dickinson、A.A. Seymour

  DOI：10.1016/j.bmcl.2004.04.074

  日期：2004.7

  A series of N-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamides were prepared and evaluated for their human beta(3) adrenergic receptor agonist activity. SAR studies led to the identification of BMS-201620 (39), a potent beta(3) full agonist (K-i = 93 nM, 93% activation). Based on its favorable safety profile, BMS-201620 was chosen for clinical evaluation. (C) 2004 Elsevier Ltd. All rights reserved.